Results 131 to 140 of about 676,629 (244)

Human Blood‐Brain Tumor Barrier on a Chip to Investigate Personalized Treatment for Glioblastoma Patients

Small, Volume 22, Issue 49, 1 September 2026.
A microfluidic model of the glioblastoma (GBM) margin was developed to mimic patient‐specific blood‐brain tumor barrier (BBTB) function and drug response. The platform revealed inter‐patient variability in barrier integrity and drug sensitivity, offering a tool for personalized therapy evaluation in GBM.
Minsu Ryoo, Gaeun Lee, Jinwoo Jung, Sujin Cho, Sharon Jeeho Ham, Nayeong Kang, Hyeongjin Ahn, Yu Jin Kim, JeongMin Sim, Jeongman Park, Juwon Kim, Sohyun Hwang, Jihwan Yoo, Youn‐Jung Kang, Jaejoon Lim, Jungho Ahn, Song Ih Ahn   +16 more
wiley   +1 more source

Prognostic value of urokinase plasminogen activator for prostatic carcinoma.

, 1994
The usefulness of routine clinical application of the urokinase plasminogen activator in prostate cancer was evaluated. The urokinase values of prostate cancer confined to the organ, with extraprostatic spread and with metastatic disease did not differ ...
Plas E, Lehmann K, Hauri D, Gautschi K
core   +1 more source

IL‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways

Allergy, Volume 81, Issue 9, Page 3171-3184, September 2026.
IL‐33 induces inflammatory gene signatures in eosinophils, characterised by the upregulation of cell surface markers, inflammatory mediators and regulatory factors, all of which were also observed in nasal polyp‐derived eosinophils. Ox‐LDL and complement fragments (C3a and C5a) promote eosinophil adhesion and survival.
Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga   +16 more
wiley   +1 more source

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors [PDF]

The Journal of cell biology, 1987
Blasi, F., Vassalli, Jean-Dominique, Dano, K.   +2 more
openaire   +3 more sources

Artificial Intelligence in Model‐Informed Drug Development: Augmentation, Acceleration, and Regulatory Preparation

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACTThe convergence of MIDD and AI represents a natural evolution from established quantitative frameworks toward a broader, more powerful computational toolbox that can address persistent MIDD challenges such as high‐dimensional data integration, complex biology, and operational constraints in evidence generation.
Hao Zhu, Ruihao Huang, Menglun Wang, Lixia Zhang, Hanrui Zhang, Yutao Gong, Rajanikanth Madabushi, Qi Liu   +7 more
wiley   +1 more source

Urokinase Plasminogen Activator Surface Receptor [PDF]

, 2020
openaire   +1 more source

Biomarkers in Schizophrenia: Current Approaches and New Developments—A Literature Review

Behavioural Neurology
Schizophrenia (SZ) is categorized as a chronic severe highly heritable brain disease. Symptoms include positive, negative, and cognitive symptoms. Despite numerous theories concerning the etiopathogenesis of SZ, the symptoms, although characteristic in ...
Alicja Sierakowska, Ewa Niewiadomska, Sebastian Łabuda, Anna Bieniasiewicz, Mateusz Roszak, Beata Łabuz-Roszak   +5 more
doaj   +1 more source

Urokinase -type Plasminogen Activator System in Human Breast Cancer [PDF]

, 2013
Urokinase plasminogen activator (uPA), urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1(PAI-1) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a ...
Al-Rawi, Ali Hussien Al-Khafaji, Al-Jubouri, Aftan Faeza, Salim Reyadh   +4 more
core  

The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells

, 2000
Single-chain urokinase-type plasminogen activator (scu-PA) is cleaved by thrombin, resulting in an inactive molecule called thrombin-cleaved two-chain urokinase-type plasminogen activator (tcu-PA/T). There is no knowledge about cell-mediated inactivation
Collen, A., Rijken, D.C., Grimbergen, J.M., Jie, A.F.H., Braat, E.A.M.   +4 more
core  

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin

Clinical Pharmacology: Advances and Applications, 2018
Felix Oh,1 Deborah Todhunter,1 Elizabeth Taras,1 Daniel A Vallera,1,2 Antonella Borgatti2,3 1Department of Therapeutic Radiology-Radiation Oncology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 2Animal Cancer Care and Research ...
Oh F, Todhunter D, Taras E, Vallera DA, Borgatti A   +4 more
doaj